Desager J P, Costermans J, Verberckmoes R, Harvengt C
Nephron. 1982;31(1):51-4. doi: 10.1159/000182614.
The influence of hemodialysis on plasma fenofibric acid kinetics has been investigated in patients with chronic renal failure given 300 mg of fenofibrate in a single oral dose. A very pronounced lengthening of the fenofibric acid plasma decay was observed in both hemodialyzed (n = 6) and nonhemodialyzed (n = 9) patients. Hemodialysis did not modify the plasma levels and the ultrafiltrates contained very small amounts of fenofibric acid. The repeated daily administration of 100 mg of fenofibrate during 2 weeks in 5 renal patients on regular hemodialysis resulted in increasing plasma levels and led to progressive cumulation of fenofibric acid. Plasma fenofibric acid conjugates could not be detected. No particular clinical side effects or increase of CPK, GOT, GPT were be observed.
在单次口服300毫克非诺贝特的慢性肾衰竭患者中，研究了血液透析对血浆非诺贝特酸动力学的影响。在接受血液透析的患者（n = 6）和未接受血液透析的患者（n = 9）中均观察到非诺贝特酸血浆半衰期显著延长。血液透析未改变血浆水平，超滤液中含极少量的非诺贝特酸。在5例定期进行血液透析的肾病患者中，连续2周每日重复给予100毫克非诺贝特，导致血浆水平升高，并使非诺贝特酸逐渐蓄积。未检测到血浆非诺贝特酸结合物。未观察到特殊的临床副作用，也未观察到肌酸磷酸激酶（CPK）、谷草转氨酶（GOT）、谷丙转氨酶（GPT）升高。
